Brokerages Set B2Gold Corp. (TSE:BTO) Target Price at C$5.43

Share on StockTwits

B2Gold Corp. (TSE:BTO) (NYSE:BTG) has been assigned an average rating of “Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is C$5.43.

A number of analysts recently commented on BTO shares. Royal Bank of Canada reiterated an “underperform” rating and set a GBX 215 ($2.81) price target on shares of in a report on Wednesday, June 26th. Raymond James reiterated a “hold” rating on shares of Snc-Lavalin Group in a report on Wednesday, July 3rd. National Bank Financial lowered Detour Gold to a “hold” rating in a report on Friday, June 28th. Finally, Canaccord Genuity lifted their price target on B2Gold from C$5.25 to C$5.75 in a report on Monday, June 3rd.

Shares of BTO stock traded up C$0.14 during trading hours on Thursday, reaching C$4.34. The company had a trading volume of 5,455,919 shares, compared to its average volume of 3,055,923. The firm has a fifty day moving average of C$3.89. The company has a market capitalization of $4.09 billion and a P/E ratio of -620.00. B2Gold has a 12 month low of C$2.77 and a 12 month high of C$4.40. The company has a current ratio of 2.04, a quick ratio of 0.88 and a debt-to-equity ratio of 28.33.

B2Gold (TSE:BTO) (NYSE:BTG) last issued its quarterly earnings results on Tuesday, May 7th. The company reported C$0.05 EPS for the quarter, hitting the Zacks’ consensus estimate of C$0.05. The business had revenue of C$401.08 million for the quarter, compared to the consensus estimate of C$404.25 million. As a group, equities research analysts predict that B2Gold will post 0.24 earnings per share for the current year.

In other B2Gold news, Director Clive Thomas Johnson sold 142,195 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of C$3.56, for a total value of C$506,214.20. Following the sale, the director now directly owns 4,797,400 shares in the company, valued at C$17,078,744. Also, Senior Officer Hugh Mackinnon sold 15,000 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of C$4.03, for a total value of C$60,450.00. Following the completion of the sale, the insider now owns 322,654 shares in the company, valued at C$1,300,295.62. Insiders have sold 214,052 shares of company stock worth $788,575 over the last quarter.

About B2Gold

B2Gold Corp., together with its subsidiaries, engages in the exploration and development of mineral properties for gold deposits in Nicaragua, the Philippines, Mali, Colombia, Burkina Faso, and Namibia. The company primarily holds 80% interest in the Fekola mine, an open pit gold mine located in Mali; 90% interest in the Otjikoto gold mine located north of Windhoek, Namibia; the Masbate gold project located in the south-east of Manila, the Philippines; and 100% interest in the El Limon mine, an underground gold mine located in northwestern Nicaragua.

Further Reading: What is a conference call?

Analyst Recommendations for B2Gold (TSE:BTO)

Receive News & Ratings for B2Gold Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for B2Gold and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.